STATUS OF ORPHAN DRUGS AND REIMBURSEMENT RECOMMENDATIONS AND DECISIONS IN ANALYSED EUROPEAN COUNTRIES

被引：0
|
作者：
Kawalec, P. [1 ]
Malinowski, K. [1 ]
机构：
[1] Jagiellonian Univ, Coll Med, Krakow, Poland
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1450
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY133
引用
收藏
页码：A598 / A599
页数：2
相关论文
共 50 条
  • [41] AN EUROPEAN OVERVIEW OF THE FUTURE CHANGES IN EVIDENCE REQUIREMENTS FOR THE REIMBURSEMENT OF ORPHAN DRUGS-A STAKEHOLDER ANALYSIS
    Krueger, L. J.
    Tamminga, J. J.
    Wijnen, B.
    Hiligsmann, M.
    Evers, S. M.
    VALUE IN HEALTH, 2014, 17 (03) : A236 - A236
  • [42] Pricing and reimbursement of orphan drugs: the need for more transparency
    Steven Simoens
    Orphanet Journal of Rare Diseases, 6
  • [43] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
  • [44] Pricing and reimbursement of orphan drugs: the need for more transparency
    Simoens, Steven
    ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [45] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [46] Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis
    Garattini, Livio
    Cornago, Dante
    De Compadri, Paola
    HEALTH POLICY, 2007, 82 (03) : 330 - 339
  • [47] Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    Denis, Alain
    Mergaert, Lut
    Fostier, Christel
    Cleemput, Irina
    Hulstaert, Frank
    Simoens, Steven
    PHARMACOECONOMICS, 2011, 29 (10) : 883 - 893
  • [48] Reimbursement of orphan drugs in Belgium: what (else) matters?
    Eline Picavet
    David Cassiman
    Steven Simoens
    Orphanet Journal of Rare Diseases, 9
  • [49] Critical Assessment of Belgian Reimbursement Dossiers of Orphan Drugs
    Alain Denis
    Lut Mergaert
    Christel Fostier
    Irina Cleemput
    Frank Hulstaert
    Steven Simoens
    PharmacoEconomics, 2011, 29 : 883 - 893
  • [50] MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
    Vollmer, L.
    Prada, M.
    Benazet, F.
    Berard, I
    Lopez, N.
    Guterres, S.
    Walzer, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
12345